Watson resubmits Oxytrol NDA
Executive Summary
Watson resubmits Oxytrol (oxybutynin) NDA for treatment of overactive bladder with Phase IIIb trial data. FDA issued "not approvable" letter for Oxytrol in March (1"The Pink Sheet" April 1, p. 24). Agency decision is due by Feb. 28...
You may also be interested in...
Watson Oxytrol Approval Expected In 2003; Patch Is “Not Approvable” At FDA
Watson Pharmaceuticals expects the overactive bladder patch Oxytrol to be cleared by FDA in the first quarter of 2003, following receipt of a "not approvable" letter March 26
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.